Key result
Targeting serotonin synthesis or signaling shows promise as a novel therapeutic approach for PAH.
Why the study?
Serotonin synthesis is elevated in pulmonary artery endothelial cells in pulmonary arterial hypertension and associated with its pathologies, motivating a review of serotonin in PAH and potential therapeutic targets.
Design
Review
Authors
Loading...
Serotonin pathway targeting merits preclinical validation in PAH; leaves open whether it improves clinical outcomes.
This review highlights the pathogenic role of serotonin in pulmonary arterial hypertension and suggests targeting its synthesis or signaling as a potential therapeutic strategy.
MacLean et al. (2022) conducted a review in Pulmonary arterial hypertension (PAH). Targeting serotonin synthesis or signaling was evaluated. Targeting serotonin synthesis or signaling is a promising novel alternative approach which may lead to novel therapies for pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: